Immediate Impact
57 standout
Citing Papers
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
2024 Standout
New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
Works of Edward Dow being referenced
A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer
2004
Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas
1999
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Edward Dow | 93 | 102 | 55 | 87 | 15 | 270 | |
| P. Maubach | 37 | 83 | 58 | 126 | 21 | 317 | |
| Ilaria Rambaldi | 160 | 85 | 34 | 135 | 14 | 263 | |
| Masae Matsumoto | 122 | 71 | 75 | 83 | 16 | 304 | |
| Hans Strauß | 48 | 59 | 45 | 83 | 12 | 268 | |
| Senaka Peter | 100 | 40 | 69 | 84 | 17 | 292 | |
| Christian Hosius | 58 | 83 | 53 | 93 | 19 | 224 | |
| Jun Kuyama | 194 | 91 | 30 | 36 | 17 | 321 | |
| Carlos Arce‐Lara | 67 | 122 | 98 | 145 | 20 | 273 | |
| Christine Fritz | 27 | 53 | 78 | 62 | 11 | 204 | |
| Maria Koumpou | 28 | 66 | 121 | 134 | 12 | 310 |
All Works
Loading papers...